The United States Food and Drug Administration (USFDA) has directed Glenmark Pharmaceuticals, Granules India, and Zydus Lifesciences to recall certain pharmaceutical products from the US market due to quality and safety concerns. The recalls underscore the critical importance of regulatory compliance in global drug exports. While the specific products and batches vary by company, the action highlights challenges faced by Indian pharmaceutical firms operating in stringent overseas markets.